 Luminol breast cancer is the most common type of breast cancer, accounting for over 70% of all cases. Despite being initially responsive to treatments, this type of cancer can still be prone to occurrences and metastases up to 15 years later. Researchers have identified a protein called fatty acid amide hydrolase, FAAH, which is present in high levels in some patients with luminal breast cancer. This protein has been found to be a predictor of long-term survival in these patients, suggesting that it may be used as a biomarker to help identify those at greater risk of recurrence or metastasis. Additionally, researchers have shown that blocking FAAH activity can prevent tumors from growing and spreading in both cell and animal models of breast cancer. These results suggest that FAAH could potentially be used as a therapeutic target for treating metastatic luminal breast cancer. This article was authored by Isabel Tandidor, Marta Sejovilla, Sandra Blasco Bonito, and others. We are article.tv, links in the description below.